Immunovaccine CEO to reveal firm's latest vaccine work at conference

Immunovaccine CEO Marc Mansour will speak on the company's vaccine work at the BIO CEO and Investor Conference next week. | Contributed photo

Immunovaccine CEO Marc Mansour said on Tuesday that he plans to attend the 17th annual BIO CEO & Investor Conference next week.

Immuniovaccine, a clinical-stage vaccine and immunotherapy company, develops immunotherapies for infectious diseases and other cancers using the DepoVax platform, a patented formulation that exposes the immune system to antigens.

Mansour said he plans to speak on Immunovaccine's latest developments on vaccine candidates for cancer, anthrax, Ebola and respiratory syncytial virus. DepoVax is used to develop the vaccines for each of those diseases.

DepoVax has the potential to create vaccines that will be effective in a single dose, Immunovaccine said.

“The DepoVax platform is flexible and can be used with a broad range of target antigens for preventative or therapeutic applications,” the company said. “The technology is designed to be commercially scalable, with the potential for years of shelf-life stability.”

The company also has two T cell therapies for cancer through a first phase of human clinical trials. The lead vaccine, called DPX-Survivac, will soon be entering into phase 2 of its clinical trials for ovarian and brain cancer.

The conference will begin on Monday at 8 a.m. EST at the Louis XVI room at the Waldorf Astoria New York Hotel.

Organizations in this story

Immunovaccine 1344 Summer St Halifax, NS B3H 0A8

Get notified the next time we write about Immunovaccine!